Medical News

RSS

PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced preliminary data from a single site participating in the multicenter Phase 2 clinical trial that showed that Positron Emission Tomography (PET) imaging with its novel investigational agent flurpiridaz F 18 injection (formerly known as BMS747158) provided better image quality than technetium-99m sestamibi single photon emission computed tomography (SPECT), the current standard for the non-invasive detection of coronary artery disease (CAD).

8 Jun 2010

Community-based health promotion program reduces heart disease, stroke in seniors: Researcher

A community-based health promotion program delivered by over 500 peer volunteers significantly reduces heart disease and stroke in seniors, Canadian Stroke Network researcher Dr. Janusz Kaczorowski told the Canadian Stroke Congress today.

8 Jun 2010

UNFPA, CARE partner to improve health of women and girls

Leaders from UNFPA, United Nations Population Fund, and CARE International announced today at the Women Deliver Conference an agreement to enhance collaboration on maternal health programs in more than 25 countries. This unique collaboration will bring together UNFPA's effective work with national governments and CARE's expertise in engaging local communities.

8 Jun 2010

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

Chronix Biomedical today reported new data further demonstrating that its DNA blood tests have the potential to accurately detect early stage breast and prostate cancers. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

8 Jun 2010

Tenet Healthcare withdraws from preliminary discussions regarding potential acquisition of Healthscope

Tenet Healthcare Corporation today announced it has withdrawn from preliminary discussions regarding a potential acquisition of the Australian private hospital operator Healthscope Limited. Due to the sequence of events associated with the acquisition process, including the premature disclosure of non-public information regarding Tenet's preliminary interest in Healthscope, Tenet has been unable to complete the work necessary to thoroughly convey to shareholders the potential value, including the inherent risks and opportunities, of this transaction.

8 Jun 2010

APP's lyophilized Oxaliplatin for Injection receives FDA marketing approval

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today it received approval from the U.S. Food and Drug Administration to market Oxaliplatin for Injection (lyophilized), 50 mg and 100 mg.

8 Jun 2010

Long sleep duration associated with elevated prevalence of metabolic syndrome in older adults: Study

Long sleep duration is associated with an elevated prevalence of metabolic syndrome in older adults, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

8 Jun 2010

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from an ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, AP24534, in patients with resistant and refractory chronic myeloid leukemia (CML). The data confirm strong clinical evidence of hematologic, cytogenetic and molecular anti-leukemia activity of AP24534, a multi-targeted kinase inhibitor, in heavily pretreated patients with CML, including those with the T315I mutation of the target protein, BCR-ABL.

8 Jun 2010

Health Impact Project announces six grants to conduct HIAs at state and local levels

The Health Impact Project, a collaboration of the Robert Wood Johnson Foundation and The Pew Charitable Trusts, today announced more than $1 million in grants to six projects that will conduct health impact assessments at the state and local levels.

8 Jun 2010

Greatbatch celebrates 50th anniversary of first successful US human cardiac pacemaker implantation

Greatbatch, Inc. is proud to join the medical community in celebrating the 50th anniversary of the first successful implantation of the human cardiac pacemaker in the United States. The pacemaker was designed, developed and implanted by Wilson Greatbatch in conjunction with William M. Chardack, M.D. and Andrew A. Gage, M.D.

8 Jun 2010

Report finds racial and ethnic disparities in children's health and health care

Within a comprehensive health insurance system, black and Hispanic children appear more likely than white children to have asthma and their outcomes are often worse, according to a report posted online today that will appear in the August print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

8 Jun 2010

Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer

Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo.

8 Jun 2010

Older veterans with PTSD more likely to develop dementia: Report

Older veterans with post-traumatic stress disorder appear more likely to develop dementia over a seven-year period than those without PTSD, according to a report in the June issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Jun 2010

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

OncoGenex Pharmaceuticals, Inc. today announced final results from a Phase 1 trial. The primary purpose of this trial was to evaluate the safety and tolerability of OGX-427 up to doses of 1000 mg for the treatment of various solid tumors. Patients enrolled had a diagnosis of castrate resistant prostate cancer, breast cancer, ovarian cancer or non-small cell lung cancer.

8 Jun 2010

ZIOPHARM presents positive data from PICASSO Phase II trial for soft tissue sarcoma at 46th ASCO

ZIOPHARM Oncology, Inc. announced today that Dr. Claire Verschraegen of the University of New Mexico, Albuquerque and first author of the abstract, "A phase II randomized controlled trial of palifosfamide plus doxorubicin vs. doxorubicin in patients with soft tissue sarcoma (PICASSO)," (Abstract #10004) presented in an oral session today updated positive data from PICASSO.

8 Jun 2010

Protein p53 becomes activated to control creation of ova and spermatozoids: Study

Protein 53 is very important in protecting against cancer given that it prevents cancer-causing mutations from accumulating and its inactivation is closely linked to the proliferation of tumour cells. UAB lecturer Ignasi Roig participated in the study. Formed by an international research team, the study served to discover that this protein played an unexpected physiological role: it also becomes activated during the formation process of ova and spermatozoids.

8 Jun 2010

US Court lifts stay on Cook's endovascular technology patent infringement case against Endologix

The United States District Court, Southern District of Indiana, has ruled in favor of Cook Incorporated in its decision to lift the stay on Cook's patent infringement case against Endologix, Inc.. With this ruling, the case, filed by Cook on October 6, 2009, will now proceed. The complaint claims infringement by Endologix of two Cook patents for endovascular technologies, one of Cook's leading technology portfolios.

8 Jun 2010

Excessive sleepiness more common in the U.S. than in Europe: Research

Excessive sleepiness is more common in the U.S. than in Europe, which raises concerns for public health and safety, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

8 Jun 2010

Gates Foundation to invest $1.5 billion for integrated women's and children's health programs

Melinda Gates today urged global leaders to make women's and children's health a top priority, and announced that the Gates Foundation will invest $1.5 billion over the next five years to support maternal and child health, family planning, and nutrition programs in developing countries.

8 Jun 2010

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened Investigational New Drug application (IND) with the United States Food and Drug Administration (US FDA). The IND is for Can-Fite's lead compound, CF101, for the treatment of patients with psoriasis. This is the third US IND for CF101, and the fourth for Can-Fite.

8 Jun 2010

Medical News

PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection

Community-based health promotion program reduces heart disease, stroke in seniors: Researcher

UNFPA, CARE partner to improve health of women and girls

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

Tenet Healthcare withdraws from preliminary discussions regarding potential acquisition of Healthscope

APP's lyophilized Oxaliplatin for Injection receives FDA marketing approval

Long sleep duration associated with elevated prevalence of metabolic syndrome in older adults: Study

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

Health Impact Project announces six grants to conduct HIAs at state and local levels

Greatbatch celebrates 50th anniversary of first successful US human cardiac pacemaker implantation

Report finds racial and ethnic disparities in children's health and health care

Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer

Older veterans with PTSD more likely to develop dementia: Report

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

ZIOPHARM presents positive data from PICASSO Phase II trial for soft tissue sarcoma at 46th ASCO

Protein p53 becomes activated to control creation of ova and spermatozoids: Study

US Court lifts stay on Cook's endovascular technology patent infringement case against Endologix

Excessive sleepiness more common in the U.S. than in Europe: Research

Gates Foundation to invest $1.5 billion for integrated women's and children's health programs

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News